Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01568073 |
|
Recruitment Status :
Completed
First Posted : April 2, 2012
Results First Posted : January 8, 2015
Last Update Posted : September 18, 2015
|
Sponsor:
Bial - Portela C S.A.
Information provided by (Responsible Party):
Bial - Portela C S.A.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study aims to demonstrate the efficacy and safety of BIA 9-1067, compared with entacapone or placebo, when administered with the existing treatment of L-DOPA plus a Dopa Decarboxylase Inhibitor (DDCI), in patients with Parkinson's Disease (PD) and end-of-dose motor fluctuations.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Parkinson's Disease | Drug: BIA 9-1067 Drug: Entacapone Drug: Placebo Drug: Levodopa Drug: Carbidopa Drug: Benserazide | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 600 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo- and Active-controlled, Parallel-group, Multicentre Clinical Study |
| Study Start Date : | March 2011 |
| Actual Primary Completion Date : | November 2013 |
| Actual Study Completion Date : | November 2013 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Parkinson disease
MedlinePlus related topics:
Parkinson's Disease
| Arm | Intervention/treatment |
|---|---|
|
Experimental: BIA 9-1067
OPC, Opicapone
|
Drug: BIA 9-1067
5, 25 and 50 mg of BIA 9-1067 (once-daily)
Other Name: OPC, Opicapone Drug: Levodopa Other Name: L-Dopa Drug: Carbidopa DOPA decarboxylase inhibitor Drug: Benserazide DOPA decarboxylase inhibitor |
|
Active Comparator: Entacapone
Comtan®; Active comparator
|
Drug: Entacapone
200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
Other Name: Comtan® Drug: Levodopa Other Name: L-Dopa Drug: Carbidopa DOPA decarboxylase inhibitor Drug: Benserazide DOPA decarboxylase inhibitor |
|
Placebo Comparator: Placebo
PLC, Placebo
|
Drug: Placebo
200 mg
Other Name: PLC Drug: Levodopa Other Name: L-Dopa Drug: Carbidopa DOPA decarboxylase inhibitor Drug: Benserazide DOPA decarboxylase inhibitor |
Primary Outcome Measures :
- Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo, [ Time Frame: 14 to 15 weeks ]The primary efficacy variable will be the change from baseline in absolute OFF-time at the end of the DB period, This results refers when administered with the existing treatment of L-DOPA plus a DDCI, in patients with PD and end-of-dose motor fluctuations
Secondary Outcome Measures :
- Total UPDRS SCORE (I, II (ON), and III) [ Time Frame: 14 to 15 weeks ]
Total UPDRS (Part I, II (ON) and III)
- UPDRS I evaluation of mentation, behavior, and mood
- UPDRS II self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food
- UPDRS III clinician-scored monitored motor evaluation The UPDRS I, II and III scores and subscores are calculated as the sum of all individual items. If one or two items in a scale are missing, they will be imputed with the mean of the non-missing items of that scale.
Subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe
The final cumulative score will range from 0 (no disability) to 199 (total disability).
- Parkinson's Disease Sleep Scale (PDSS) [ Time Frame: 14 to 15 weeks ]
The Parkinson's disease Sleep Scale (PDSS) is a specific scale for the assessment of sleep disturbances in subjects with PD. The PDSS score is calculated as the sum of all single items. If one or two items are missing, they will be imputed with the mean of the non-missing items. If three or more items are missing, no imputation will be done and the score will be set to missing.
Subscale has 0-10 ratings, where 0 = severe and 10 = normal
The PDSS total score is a sum score of all 15 questions and ranges from 0 to 150, with lower scores meaning more disability.
- Non-motor Symptoms Scale (NMSS) [ Time Frame: 14 to 15 weeks ]
The Non-motor Symptoms Scale (NMSS) consists of 30 questions, covering 9 dimensions, whereby each item is scored for severity and frequency: Severity None 0 Mild (symptoms present but causes little distress) 1 Moderate (some distress or disturbance to subject) 2 Severe (major source of distress or disturbance to subject) 3
Frequency Rarely (<1/wk) 1 Often (1/wk) 2 Frequent (several times per week) 3 Very Frequent (daily or all the time) 4
The product of frequency and severity is calculated for each item and each dimension score is defined as the sum of the frequency*severity of the respective items. If frequency or severity of a single item is missing, the domain score will not be calculated. The NMSS total score is defined as the sum of all domain scores.
The NMSS total score is calculated by adding all domain scores (0-360), and lower scores mean less disability.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Years to 83 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
V1 (Screening, up to 14 days before V2)
- Able to comprehend and willing to sign an informed consent form.
- Male and female subjects between 30 and 83 years old, inclusive.
- Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria for at least 3 years.
- Disease severity Stages I-III (modified Hoehn &Yahr staging) at ON.
- Treated with L-DOPA/DDCI for at least 1 year with clear clinical improvement as per investigator's judgment.
- Treated with 3 to 8 daily doses of L-DOPA/DDCI, which can include a slow-release formulation.
- On a stable regimen of L-DOPA/DDCI and other anti-PD drugs for at least 4 weeks before screening.
- Signs of "wearing-off" phenomenon (end-of-dose deterioration) for a minimum of 4 weeks before screening, with average total daily OFF time while awake of at least 1.5 hours, excluding the early morning pre-first dose OFF, despite optimal anti-PD therapy (based on the investigator's judgment).
- Able to keep reliable diaries of motor fluctuations (alone or with family/caregiver assistance).
- Amenorrheic for at least 1 year or surgically sterile for at least 6 months before screening. Females of childbearing potential must be using an effective non-hormonal contraceptive method.
V2 (Randomisation, Day 0)
- Have filled-in self-rating diary charts in accordance with the diary chart instructions and with ≤ 3 errors per day.
- At least 1.5 OFF hours per day, excluding the early morning pre-first dose OFF period (i.e. the time between wake-up and response to the first L DOPA/DDCI dosage), as recorded in the self-rating diary for at least 2 of the 3 days preceding V2.
- Results of the screening laboratory tests are considered acceptable by the investigator (i.e. not clinically relevant for the well-being of the subject or for the purpose of the study).
Exclusion Criteria:
V1 (Screening, up to 14 days before V2)
- Non-idiopathic PD (atypical parkinsonism, secondary [acquired or symptomatic] parkinsonism, Parkinson-plus syndrome).
- Dyskinesia disability score > 3 in the Unified Parkinson's Disease Rating Scale (UPDRS) Sub-section IV A, item 33.
- Severe and/or unpredictable OFF periods.
- Treatment with prohibited medication: tolcapone, neuroleptics, venlafaxine, monoamine oxidase inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or rasagiline up to 1 mg/day), or antiemetics with antidopaminergic action (except domperidone) within the month before screening.
- Previous use of entacapone.
- Treatment with apomorphine, alpha-methyldopa, or reserpine within the month before screening or likely to be needed at any time during the study.
- Dosage change of concomitant anti-PD medication within 4 weeks of screening.
- Previous or planned (during the entire study duration, including the OL period) deep brain stimulation.
- Previous stereotactic surgery (e.g. pallidotomy, thalamotomy) for PD or with planned stereotactic surgery during the study period.
- Any IMP within the 3 months (or within 5 half-lives, whichever is longer) before screening.
- Any medical condition that might place the subject at increased risk or interfere with assessments.
- Past (within the past year) or present history of suicidal ideation or suicide attempts.
- Current or previous (within the past year) diagnosis of major depressive disorder, mania, bipolar disorder, psychosis, dysthymia, generalised anxiety disorder, alcohol or substance abuse excluding caffeine or nicotine, impulse control disorders (e.g. pathological gambling), dementia or eating disorders according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV) American Psychiatric Association, 2000 criteria, as determined by the investigator.
- A clinically relevant electrocardiogram (ECG) abnormality (relevance should be assessed by a cardiologist if needed).
- Current evidence of unstable cardiovascular disease, including but not limited to uncontrolled hypertension, myocardial infarction with important systolic or diastolic dysfunction, unstable angina, congestive heart failure (New York Heart Association class ≥ III), and significant cardiac arrhythmia (Mobitz II 2nd or 3rd degree AV block or any other arrhythmia causing haemodynamic repercussions as symptomatic bradycardia or syncope).
- Prior renal transplant or current renal dialysis.
- Pheochromocytoma, paraganglioma, or other catecholamine secretive neoplasm.
- Known hypersensitivity to the ingredients of IMPs used.
- History of neuroleptic malignant syndrome (NMS) or NMS-like syndromes, or non-traumatic rhabdomyolysis.
- History of or current cancer disease, which in the investigator's opinion would exclude the subject from the study (e.g. melanoma, prostate cancer).
- Unstable active narrow-angle or unstable wide-angle glaucoma.
- History of or current evidence of any relevant disease in the context of this study, i.e. with respect to the safety of the subject or related to the study conditions, e.g. which may influence the absorption or metabolism (such as a relevant liver disease) of the IMP.
- Pregnant or breastfeeding. V2 (Randomisation, Day 0)
- Any abnormality in the liver enzymes (alanine aminotransferase and/or aspartate aminotransferase) > 2 times the upper limit of the normal range, in the screening laboratory tests results.
- Plasma sodium < 130 mmol/L, white blood cell count < 3000 cells/mm3, or any other relevant clinical laboratory abnormality in the screening laboratory tests results that, in the investigator's opinion, may compromise the subject's safety.
- Inadequate compliance to concomitant L-DOPA/DDCI and other anti-PD drugs during the Screening period.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01568073
Locations
| Portugal | |
| Bial - Portela & Cª, S.A. | |
| S. Mamede do Coronado, Portugal, 4745-457 | |
Sponsors and Collaborators
Bial - Portela C S.A.
Investigators
| Principal Investigator: | Joaquim Ferreira, MD, PhD | Centro Hospitalar de Lisboa Norte, EPE - Hospital de Staª Maria-Centro de Estudos Egas Moniz |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Bial - Portela C S.A. |
| ClinicalTrials.gov Identifier: | NCT01568073 |
| Other Study ID Numbers: |
BIA-91067-301 2010-021860-13 ( EudraCT Number ) |
| First Posted: | April 2, 2012 Key Record Dates |
| Results First Posted: | January 8, 2015 |
| Last Update Posted: | September 18, 2015 |
| Last Verified: | September 2015 |
Keywords provided by Bial - Portela C S.A.:
|
Parkinson PD Wearing-off Levodopa/DDCI |
Additional relevant MeSH terms:
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases Levodopa Carbidopa Opicapone |
Entacapone Benserazide Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Aromatic Amino Acid Decarboxylase Inhibitors Enzyme Inhibitors Catechol O-Methyltransferase Inhibitors |